Company
ASX:RAD
Radiopharm Theranostics is a clinical-stage biotech company revolutionizing cancer care through the development of first-in-class radiopharmaceuticals. The company is advancing a pipeline of distinct radiopharmaceutical technologies for novel oncology targets—avoiding "me-too" targets like Prostate-Specific Membrane Antigen (PSMA), Fibroblast Activation Protein (FAP) or Somatostatin Receptor 2 (SSTR2).
101 stories · page 4 of 6
“DUNP19 has demonstrated promise for several indications, but its potential as first in class therapy for osteosarcoma is particularly exciting, considering the high unmet need in the children and adolescents who typically suffer this disea
“We are proud to have entered an LOI with GenesisCare, Australia’s largest provider of integrated cancer care, to support a trial for our innovative radiopharmaceutical therapy targeting non-small cell lung cancer, pending ethics approval f
The company is planning face-to-face meetings as part of an upcoming roadshow to update investors on its progress.
The supply agreement is for an initial period of three years and may be extended for a further two successive 12-month periods.
“There is tremendous growth projected for radiopharmaceutical therapies over the next five to 10 years, when you can combine the right molecule with the right isotope in areas of high unmet medical need,” said CEO Riccardo Canevari.
It has been a busy time for the company, with plans advancing for the clinical development of a pancreatic cancer treatment in the US, and the sealing of an isotope supply deal with TerraPower.
Larkin will bring big pharma and nuclear medicine expertise, as well as corporate leadership know-how, to the non-executive role.
The company, through nuclear company TerraPower, has harnessed the rare medical isotope Actinium-225 for use in its radiopharmaceutical therapies for cancer.
The company adds the intellectual property for the cancer-fighting nanobodies to its stable of cancer diagnosis and treatment assets.
Radiopharm has licensed a diversified pipeline of Radiopharmaceutical Therapies (RPTs) spanning from peptides, humanized monoclonal antibodies, and small molecules addressing roughly 75% of the causes of death from cancer.
“The new appointments complement the team of industry experts assembled by RAD this year as it continues to test its portfolio of licensed assets that include peptides, small molecules and monoclonal antibodies,” says MD.
The Phase 1 trial of 40 patients in Shanghai propels the company towards confirming its asset, RAD201, as a useful diagnostic tool in breast cancer.
The broker has assigned RAD a value of $0.86 per share – $0.76 per share on a fully diluted basis – which accounts for the strongest assets in the company’s pipeline, including five candidates across a range of cancer indications.
The article concluded that of all integrins, avβ6, the variety used by Radiopharm, is "arguably the most promising target structure for radiotheranostics," recognising its broad clinical scope across oncology as well as fibrotic diseases, w
“We are thrilled to have Dr Hurvitz join our highly experienced scientific advisory board,” says Radiopharm CEO and managing director.
As the latest company to hit the local share market, RAD is prepared to advance its radiopharmaceutical pipeline and develop solutions for the diagnostic and therapeutic spheres.
